RediTrex Now Available for RA, pJIA, Psoriasis Treatment
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Diagnosis & Disease Information
Study Supports Switching Between Upadacitinib and Adalimumab in RA
Researchers evaluated the safety and efficacy of switching between upadacitinib and adalimumab in patients with rheumatoid arthritis with nonresponse or incomplete response to initial therapy.
Glucocorticoids Linked to Hospitalized Infection Risk in RA
Risk for hospitalized infections up for patients with RA receiving DMARDs with continued glucocorticoid use
Curcuma longa Extract Improves Knee Pain in Osteoarthritis
CL improved pain but did not change effusion-synovitis volume or cartilage composition.
Early Therapy for Rheumatoid Arthritis May Slow Heart Disease
RA treatment response does not appear to impact improvement in vascular stiffness.
MPR Weekly Dose Podcast Episode 48
Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.
FDA Rejects Filgotinib NDA for Rheumatoid Arthritis
The FDA has issued a Complete Response Letter (CRL) to Gilead Sciences related to the New Drug Application (NDA) for filgotinib in the treatment of moderately to severely active rheumatoid arthritis.
Biosimilar Hulio Gets FDA Approval
The Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Upadacitinib Beats Methotrexate in Early Rheumatoid Arthritis
Significantly better clinical, radiographic, patient-reported outcomes seen with upadacitinib.
Upadacitinib Compared to Abatacept in Rheumatoid Arthritis Study
Results from the phase 3 SELECT-CHOICE study comparing treatment with upadacitinib (Rinvoq™; AbbVie), a Janus kinase inhibitor, to abatacept (Orencia™; Bristol Myers Squibb), a selective T cell costimulation modulator, in adults with moderate to severe active rheumatoid arthritis.
